Bilimsel çalışmalar

Prof. Dr. İrfan Çiçin

339 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİMETASTATİK PROSTAT KANSERİ (KDMPK)HASTALARINDA 1. BASAMAK ANTİ- ANDROJENTEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ

    AYBU AVESIS, 2019

    Kaynak: OpenAlex

  2. GERIATRIK (≥75 YAS), KASTRASYON DIRENCLI METASTATIK PROSTAT KANSERI (KDMPK) HASTALARINDA 1. BASAMAK ANTI- ANDROJEN TEDAVI SONUCLARI- GERCEK YASAM VERISI

    AYBU AVESIS, 2019

    Kaynak: OpenAlex

  3. Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi

    AYBU AVESIS, 2019

    Kaynak: OpenAlex

  4. Kastrasyon Direncli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yas) Hastalarda 1. Basamak Dosetaksel Tedavi Sonucları- Gercek Yasam Verisi

    AYBU AVESIS, 2019

    Kaynak: OpenAlex

  5. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer

    Clinical and Translational Oncology, 2019

    DOI 10.1007/s12094-019-02079-x PMID 30924091 4 atıf (Europe PMC) Kaynak: ORCID

  6. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib

    Clinical and Translational Oncology, 2019

    DOI 10.1007/s12094-019-02080-4 PMID 30868388 19 atıf (Europe PMC) Kaynak: ORCID

  7. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

    Cancer Chemotherapy and Pharmacology, 2018

    DOI 10.1007/s00280-018-3713-6 PMID 30374523 13 atıf (Europe PMC) Kaynak: OpenAlex

  8. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

    Cancer Chemotherapy and Pharmacology, 2018

    DOI 10.1007/s00280-018-3712-7 PMID 30377778 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  9. Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experince from Turkey

    Van Yüzüncü Yıl University Academic Data Management System, 2018

    Kaynak: OpenAlex

  10. Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

    Bursa Uludag University - AVESIS, 2018

    Kaynak: OpenAlex

  11. CRIZOTINIB EFFICACY IN ALK-POSITIVE ADVANCEDSTAGE NON-SMALL CELL LUNG CANCER PATIENTS: A REAL-WORLD EXPERIENCE FROM TURKEY

    Kocaeli Üniversitesi - AVESİS, 2018

    Kaynak: OpenAlex

  12. Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA)

    Clinical and Applied Thrombosis/Hemostasis, 2018

    DOI 10.1177/1076029617753538 PMID 29455568 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  13. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    New England Journal of Medicine, 2018

    DOI 10.1056/nejmoa1717002 PMID 29972759 1.891 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  14. A retrospective study on potential drug interactions: A single center experience

    Journal of Oncological Sciences, 2018

    DOI 10.1016/j.jons.2018.06.001 7 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  15. An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

    European Journal of Cancer, 2018

    DOI 10.1016/s0959-8049(18)30535-5 2 atıf (OpenAlex) Kaynak: OpenAlex

  16. Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma.

    PubMed, 2018

    PMID 30358202 3 atıf (Europe PMC) Kaynak: OpenAlex

  17. Bone-Targeted Therapy in Early Breast Cancer

    Springer eBooks, 2018

    DOI 10.1007/978-3-319-96947-3_18 1 atıf (OpenAlex) Kaynak: OpenAlex

  18. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.4_suppl.207 100 atıf (OpenAlex) Kaynak: OpenAlex

  19. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.15_suppl.4090 26 atıf (OpenAlex) Kaynak: OpenAlex

  20. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.15_suppl.4019 14 atıf (OpenAlex) Kaynak: OpenAlex

  21. Bone-Targeted Therapy in Advanced Breast Cancer

    Springer eBooks, 2018

    DOI 10.1007/978-3-319-96947-3_25 Kaynak: OpenAlex

  22. Effectiveness and safety of LMWH treatment in patients with cancer diagnosed with nonhigh-risk venous thromboembolism (VTE): Results of the Turkish observational study (TREBECA).

    Journal of Clinical Oncology, 2017

    DOI 10.1200/jco.2017.35.15_suppl.e21656 Kaynak: OpenAlex

  23. EFFECTIVENESS AND SAFETY OF LMWH TREATMENT IN CANCER PATIENTS DIAGNOSED WITH NON-HIGH RISK VENOUS THROMBOEMBOLISM (VTE) - RESULTS OF TURKISH OBSERVATIONAL STUDY (TREBECA)

    Bursa Uludag University - AVESIS, 2017

    Kaynak: OpenAlex

  24. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

    The Lancet, 2017

    DOI 10.1016/s0140-6736(17)32365-6 PMID 28916371 125 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  25. K-RAS and N-RAS mutations in testicular germ cell tumors

    Bosnian Journal of Basic Medical Sciences, 2017

    DOI 10.17305/bjbms.2017.1764 PMID 28426398 20 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  26. Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis.

    PubMed, 2017

    PMID 28730760 2 atıf (Europe PMC) Kaynak: OpenAlex

  27. Outcomes of Turkish National Breast Cancer Registry.

    Journal of Clinical Oncology, 2017

    DOI 10.1200/jco.2017.35.15_suppl.e12517 3 atıf (OpenAlex) Kaynak: OpenAlex

  28. Characteristics of Turkish colorectal cancer patients and bevacizumab preference.

    Journal of Clinical Oncology, 2017

    DOI 10.1200/jco.2017.35.15_suppl.e15055 Kaynak: OpenAlex

  29. İLERİ EVREKÜÇÜK HÜCRELİ DIŞIAKCİĞER KANSERİTANI VE TEDAVİ KILAVUZU

    2017

    Kaynak: OpenAlex

  30. Clinical Features of the Patient with Multiple Primary Tumors: Single Center Experience

    Northern Clinics of Istanbul, 2017

    DOI 10.14744/nci.2017.67044 PMID 28752142 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: YÖK Akademik

  31. KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer

    Balkan Medical Journal, 2016

    DOI 10.5152/balkanmedj.2016.150610 PMID 27606136 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  32. Unknown primary adenocarcinomas: a single-center experience

    Bosnian Journal of Basic Medical Sciences, 2016

    DOI 10.17305/bjbms.2016.1495 PMID 27455119 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  33. The Effect of the Gastrectomy on Survival in Patients with Metastatic Gastric Cancer: A Study of ASMO

    Future Oncology, 2016

    DOI 10.2217/fon.15.304 PMID 26775722 8 atıf (Europe PMC) Kaynak: OpenAlex

  34. A rare cause in etiology of left atrial mass: metastatic testicular germ cell tumor

    Polish Journal of Cardio-Thoracic Surgery, 2016

    DOI 10.5114/kitp.2016.58965 PMID 27212979 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  35. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.

    PubMed, 2016

    PMID 27382940 3 atıf (Europe PMC) Kaynak: OpenAlex

  36. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

    Balkan Medical Journal, 2016

    DOI 10.5152/balkanmedj.2016.151268 PMID 27761279 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  37. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation

    Bosnian Journal of Basic Medical Sciences, 2016

    DOI 10.17305/bjbms.2016.1380 PMID 27371767 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  38. Endometrial carcinoma and paraneoplastic immune thrombocytopenia

    Journal of Oncological Sciences, 2016

    DOI 10.1016/j.jons.2016.04.006 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  39. Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides

    Springer eBooks, 2016

    DOI 10.1007/978-3-319-26012-9_42 Kaynak: OpenAlex

  40. Durable response with medroxiprogesterone acetate in metastatic renal cell carcinoma: Case report

    Journal of Oncological Sciences, 2016

    DOI 10.1016/j.jons.2016.10.003 Açık erişimli tam metinKaynak: OpenAlex

  41. Metastatik Küçük Hücreli Dışı Akciğer Kanserinde Kaç Seri Kemoterapi Verilmeli

    Turkiye Klinikleri Medical Oncology - Special Topics, 2016

    Kaynak: OpenAlex

  42. Germ Hücreli ve Stromal Over Kanserlerinde Sistemik Tedavi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2016

    Kaynak: OpenAlex

  43. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study

    Current Medical Research and Opinion, 2016

    DOI 10.1080/03007995.2016.1257984 PMID 27817239 12 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  44. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.

    PubMed, 2015

    PMID 26902020 7 atıf (Europe PMC) Kaynak: OpenAlex

  45. Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status

    Asian Pacific Journal of Cancer Prevention, 2015

    DOI 10.7314/apjcp.2015.16.6.2355 PMID 25824764 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  46. Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer

    Molecular and Clinical Oncology, 2015

    DOI 10.3892/mco.2015.592 PMID 26623070 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  47. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma

    Medical Oncology, 2015

    DOI 10.1007/s12032-014-0460-3 PMID 25572814 4 atıf (Europe PMC) Kaynak: OpenAlex

  48. Increased Dose Single-agent Gemcitabine in Platinum-taxane Resistant Metastatic Ovarian Cancer

    Tumori Journal, 2015

    DOI 10.5301/tj.5000209 PMID 25702671 2 atıf (OpenAlex) Kaynak: OpenAlex

  49. Importance of Ki-67 in human epidermal growth factor receptor 2 positive breast cancer.

    PubMed, 2015

    PMID 26214624 3 atıf (Europe PMC) Kaynak: OpenAlex

  50. Implantations of Central Venous Ports with Chest Catheter Insertion Via the Subclavian Vein in Oncology Patients: A Single Çenter Experience

    DergiPark (Istanbul University), 2015

    1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex